Case Study

Biomarkers of Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS)

The data shows that metabolomics may offer new insights into the molecular mechanisms regulating GLUT1 function and may open new avenues of treatment for GLUT1-DS.

The present study advanced the understanding of metabolic perturbations in the CSF, plasma, and urine samples of GLUT1-DS patients and GLUT1-DS patients on KD. The data showed that metabolomics may offer new insights into the molecular mechanisms regulating GLUT1 function and may open new avenues of treatment for GLUT1-DS.

Talk With An Expert About Your Project

Biomarkers of Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS)

The Challenge: Find Novel Targets for Identifying and Rare Disease GLUT1-DS

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is an inborn error of metabolism (IEM) that leads to reduced function of GLUT1. GLUT1-DS has an estimated frequency of approximately 1 in 83,000. The role of GLUT1 is to transport glucose across the blood-brain barrier (BBB); therefore, in GLUT1-DS, neurons are primarily affected by the lack of glucose. GLUT1-DS has a heterogenous clinical presentation comprising intellectual disability, movement disorders, acquired microcephaly, and seizures. Deficiency of GLUT1 results in hypoglycorrhachia, which is an abnormally low glucose concentration within the cerebrospinal fluid (CSF). Consequently, in clinical practice, the diagnostic biomarker for GLUT1-DS is a low glucose concentration in CSF. GLUT1-DS is a treatable neurological disorder; however, it is not routinely tested by newborn screening (NBS). GLUT1-DS treatment is based on a ketogenic diet (KD). Although KD is the first treatment choice for GLUT1-DS, this diet can lose its effectiveness over time in about 20% of patients. Thus, individualized therapies targeting the underlying pathophysiology of each GLUT1-DS case should be a primary goal in treating these patients. Further studies on the molecular mechanisms of KD are needed to develop novel therapeutic strategies.

Metabolon Insight: Unraveling Metabolic Mechanisms Related to Rare Disease GLUT1-DS

This study utilized two untargeted metabolomics technologies to profile plasma, urine, and CSF samples from GLUT1-DS patients on a normal diet and on a KD.¹ The goal was to unravel metabolic mechanisms and biomarkers implicated in GLUT1-DS.

The Solution: GLUT1-DS Impairs Brain Metabolism

The metabolomics approach of GLUT1-DS patients not on KD was applied to obtain a more comprehensive overview of glucose-dependent pathways in the brain. Metabolomics identified over 300 metabolites in the CSF of patients with GLUT1-DS and biomarkers associated with GLUT1-DS. Comparing the metabolic profiles of two GLUT1-DS patients to a control group showed significantly lower glycerol 3-phosphate (Gro3P) levels and higher isocitrate levels.

Metabolomic analyses of plasma from six GLUT1-DS patients on KD identified over 600 metabolites. The z-scores for 3-hydroxybutyrate, 3-methyladipate, and N-acetylglycine were elevated in the plasma and urine samples of GLUT1-DS patients on KD, highlighting their potential as biomarkers of GLUT1-DS on KD. Analyzing signaling pathways to interrogate perturbations in GLUT1-DS patients on KD demonstrated that the most affected pathway was lipid metabolism. For instance, long-chain fatty acid, phospholipid, acylcarnitine, and sphingolipid metabolism were significantly impaired in GLUT1-DS patients on KD. Analysis of the metabolomic data also demonstrated the presence of free carnitine, suggesting its consumption in GLUT1-DS patients on KD.

The Benefit: Discovering Biomarkers and Elucidating Pathogenic Mechanisms of IEM

The present study advanced the understanding of metabolic perturbations in the CSF, plasma, and urine samples of GLUT1-DS patients and GLUT1-DS patients on KD. The potential biomarkers and metabolic insights discovered in this study deserve further investigation. The data shows that metabolomics may offer new insights into the molecular mechanisms regulating GLUT1 function and may open new avenues of treatment for GLUT1-DS.

This study demonstrated that Metabolon’s technology offers novel opportunities for discovering biomarkers and elucidating pathogenic mechanisms that might lead to the diagnosis and development of novel therapies for IEM.

References

1. Cappuccio G, Pinelli M, Alagia M, et al. Biochemical phenotyping unravels novel metabolic abnormalities and potential biomarkers associated with treatment of GLUT1 deficiency with ketogenic diet. PLoS One. 2017;12(9):e0184022. doi:10.1371/journal.pone.0184022

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.